This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Lev Gerlovin is a speaker during the session titled “Assess Value When Innovating to Establish Greater Benefits Relative to Costs.”
For more information on this event, click here.
2025 has been a year of progress in the rare disease (RD) space. At CRA, we continue to leverage our cross-functional expertise in strategy, policy, analytics,...
The effectiveness and impact of the UPL implementation for Enbrel will have a strong influence on how Maryland and other states proceed with their UPL...
CRA is a proud sponsor of the event, back for its 8th edition. This half-day, high-impact conference brings together top arbitrators, counsel, experts and...
CRA is a proud sponsor of Europe’s largest congress in market access, pricing and evidence featuring 250 speakers, 10 tracks and 1500+ attendees from pharma,...
